Go to www.mysmartrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Dr. deBethizy's presentation will be webcast and accessible from the Investor Relations page of the Company's website at targacept.com. The webcast will also be available for replay on the Company's website for at least two weeks following the conference. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled start time.

((Comments on this story may be sent to health@closeupmedia.com))

Want access to these reports and real time alerts? Go to www.tradethetrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

The NASDAQ Biotechnology Index includes securities of Nasdaq-listed companies that are classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals and meet minimum requirements for market capitalization, average daily trading volume and seasoning as a public company, as well as other eligibility criteria. The index is re-ranked on a semi-annual basis in May and November. Additional information about the NASDAQ Biotechnology Index, including eligibility criteria, is available at https://indexes.nasdaqomx.com/.

About Targacept

Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders, in support of its vision of building health and restoring independence for patients. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has clinical-stage product candidates in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer's disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on its website at www.targacept.com.

SOURCE: Targacept, Inc.

Targacept, Inc. 
Alan Musso, 336-480-2186 
VP and CFO 
alan.musso@targacept.com 
or 
Linnden Communications 
Michelle Linn, 508-362-3087 
linnmich@comcast.net